Pascal Hammel

Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer

Talia Golan, Pascal Hammel, Michele Reni et al. · New England Journal of Medicine · 2019 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Eric Van Cutsem, Margaret A. Tempero, Darren Sigal et al. · Journal of Clinical Oncology · 2020 · 446 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Hedy L. Kindler, Pascal Hammel, Michele Reni et al. · Journal of Clinical Oncology · 2022 · 225 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).

Margaret A. Tempero, Eric Van Cutsem, Darren Sigal et al. · Journal of Clinical Oncology · 2020 · 114 citations

Medicine, Oncology, Pharmacology +16

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

Eric Van Cutsem, Manuel Hidalgo, Jean‐Luc Canon et al. · International Journal of Cancer · 2018 · 105 citations · Full text

Medicine, Oncology, Pharmacology +16